AEON Biopharma Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 2/6
AEON Biopharma has a total shareholder equity of $-27.9M and total debt of $13.3M, which brings its debt-to-equity ratio to -47.6%. Its total assets and total liabilities are $5.7M and $33.7M respectively.
Wichtige Informationen
-47.6%
Verhältnis von Schulden zu Eigenkapital
US$13.29m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | US$3.44m |
| Eigenkapital | -US$27.95m |
| Gesamtverbindlichkeiten | US$33.68m |
| Gesamtvermögen | US$5.73m |
Jüngste Berichte zur Finanzlage
Keine Aktualisierungen
Recent updates
Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langfristige Verbindlichkeiten: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: AEON has negative shareholder equity, which is a more serious situation than a high debt level.
Schulden abbauen: AEON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: AEON has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Vorhersage Cash Runway: AEON is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.